This article originally ran on May 15 and has been updated to include additional comments from GlaxoSmithKline.
GlaxoSmithKline said today that it has entered an agreement to purchase chemical proteomics firm Cellzome for £61 million ($99 million).
By Adam Bonislawski
University of North Carolina researchers have developed a chemical proteomics approach to measure global kinase activity and used it to investigate drug resistance in triple-negative breast cancer.
Entitled "Proteome-wide quantification of small molecule binding to cellular target proteins," the patent encompasses the company's Cellular Target Profiling, KinAffinity, and Epigenetics Target Profiling services.
Under the deal, which follows on a previous collaboration between the companies entered in 2008, Kinaxo will apply its quantitative phosphoproteomics platform PhosphoScout to assist in drug development.